Bluebird Bio Inc Net Income per Employee (BLUE), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Bluebird Bio Inc   (NASDAQ: BLUE)
 

Bluebird Bio Inc Net Income per Employee

BLUE's Quarterly Results, Trends, Rankings, Statistics
Bluebird Bio Inc 's Income per employee grew in the first quarter 2025 on a trailing twelve month basis to , the contribution of Bluebird Bio Inc 's employees, reached a new high of $ 562,250income per employee.
The Healthcare sector has seen employees of 7 other companies achieving higher income per employee. While income per employee total ranking has improved so far to 217, from total ranking in previous quarter at 2100.


What is Income per Employee Ratio?





Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

BLUE Net Income per Employee (Mar 31 2025)
I. Quarter		 (Dec 31 2024)
IV. Quarter		 (Sep 30 2024)
III. Quarter		 (Jun 30 2024)
II. Quarter		 (Mar 31 2024)
I. Quarter
Y / Y Net Income Change - 12.93 % - - -
Net Income per Employee (TTM) $ 562,250 -282 -64,702 -354,173 -648,073
BLUE's Total Ranking # 217 # 2100 # 2629 # 0 # 0
Seq. Net Income Change - 240418.97 % - - -

BLUE Company Profile >> Back to BLUE Efficiency Comparisons >> Compare BLUE Net Income per Employee to its Competitors

BLUE Net Income per Employee Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 8
Healthcare Sector # 26
Overall Market # 217

Net Income per Employee Statistics
High Average Low
$ 562,250 $ -1,529,627 $ -3,395,681
(Mar 31 2025)   (Jun 30 2021)







Companies with similar Income per Employee for 12 month ending Mar 31 2025, within Healthcare Sector Income per Employee Income 12 month ending Mar 31 2025Number of Employees Mar 31 2025
Minerva Neurosciences Inc   893,528.29 $ 6.255  Million 7 
Prestige Consumer Healthcare Inc   875,077.19 $ 498.794  Million 570 
United Therapeutics Corporation  864,785.71 $ 1,210.700  Million 1,400 
Nkgen Biotech Inc   655,730.77 $ 17.049  Million 26 
Novavax inc   639,114.82 $ 478.697  Million 749 
Cytomx Therapeutics Inc   602,942.03 $ 41.603  Million 69 
Ptc Therapeutics inc   600,245.21 $ 594.843  Million 991 
Bluebird Bio Inc   562,250.00 $ 139.438  Million 248 
Nutriband Inc   542,111.60 $ 2.711  Million 5 
Harmony Biosciences Holdings inc   521,225.26 $ 152.719  Million 293 
Amgen Inc   456,384.62 $ 5,933.000  Million 13,000 
Protagonist Therapeutics inc   425,704.55 $ 56.193  Million 132 
Krystal Biotech Inc   420,203.39 $ 123.960  Million 295 
Biomx Inc  402,950.00 $ 8.059  Million 20 
Gilead Sciences Inc   350,882.35 $ 5,965.000  Million 17,000 
Engene Therapeutics Inc   344,487.80 $ 28.248  Million 82 
Black Hawk Acquisition Corporation  329,189.50 $ 0.658  Million 2 
X4 Pharmaceuticals Inc  324,400.00 $ 14.598  Million 45 
Entrada Therapeutics Inc   319,671.05 $ 48.590  Million 152 
Adma Biologics Inc   319,584.23 $ 206.771  Million 647 
Aurinia Pharmaceuticals Inc   311,289.06 $ 39.845  Million 128 
Stoke Therapeutics Inc   295,717.65 $ 50.272  Million 170 
Regeneron Pharmaceuticals Inc   291,972.74 $ 4,499.300  Million 15,410 
Acadia Pharmaceuticals Inc   286,820.80 $ 228.883  Million 798 


Date modified: 2026-08-29T17:19:42+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.